Synapsoft logo
AI Insights from Disclosures
Searching...
Helixmith Co., Ltd 084990
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
Helixmith Co., Ltd is an R&D company established in 1996 that possesses tangible and intangible resources, capabilities, and an organization that surpass those of leading global biotech companies, spanning basic science such as candidate substance discovery and mechanism research through preclinical, analytical, process, production, quality control, regulatory, and clinical development stages. Based on global-level development experience gained through clinical trials in Korea and the United States, including U.S. FDA orphan drug and Fast Track designations and Regenerative Medicine Advanced Therapy (RMAT) designation, and abundant production, analytical, and clinical trial know-how gained through Phase 3 clinical trial experience in the United States, the company provides services based on various drug development platforms, including Plasmid DNA, Retrovirus, and AAV.
Representative Director Jang Songseon
Founded November 21, 1996
Corporation Type KOSDAQ
Industry Classification Research and experimental development on medical sciences and pharmacy
Corporate number 11011-1343930
Business number 101-81-42428
Phone Number 02-2102-7200
Fax Number 02-887-0011
Website helixmith.com
Company Address 21 Magokjungang 8-ro 7-gil, Gangseo-gu, Seoul
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant